RecruitingNot ApplicableNCT05502523

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Sponsor

Thomas Jefferson University

Enrollment

100 participants

Start Date

Aug 31, 2022

Study Type

INTERVENTIONAL

Conditions

Stage III Lung Cancer AJCC v8 Lung Non-Small Cell Carcinoma Stage II Lung Cancer AJCC v8 Stage I Lung Cancer AJCC v8

Summary

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how different surgical approaches for removing lung cancer affect the amount of cancer DNA circulating in the blood (called ctDNA). Understanding this may help doctors use blood tests to better monitor cancer after surgery. **You may be eligible if...** - You are 18 or older with confirmed or suspected early-stage (I–III) non-small cell lung cancer - You are scheduled for surgical removal of part of the lung (lobectomy or segmentectomy) as standard care **You may NOT be eligible if...** - You were diagnosed with another cancer within the last 5 years (some exceptions apply) - You received chemotherapy, immunotherapy, or radiation before surgery - You received a blood transfusion around the time of surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.